Lopinavir ritonavir contraindications: Difference between revisions
Created page with "__NOTOC__ {{Lopinavir ritonavir}} {{CMG}}; {{AE}} {{MM}} ==Contraindications== KALETRA is contraindicated in patients with previously demonstrated clinically significant hype..." |
No edit summary |
||
| Line 9: | Line 9: | ||
Co-administration of KALETRA is contraindicated with potent CYP3A inducers where significantly reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and cross-resistance. These drugs are listed in Table 3.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = KALETRA (LOPINAVIR AND RITONAVIR) TABLET, FILM COATED KALETRA (LOPINAVIR AND RITONAVIR) SOLUTION [ABBVIE INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8290add3-4449-4e58-6c97-8fe1eec972e3 | publisher = | date = | accessdate}}</ref> | Co-administration of KALETRA is contraindicated with potent CYP3A inducers where significantly reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and cross-resistance. These drugs are listed in Table 3.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = KALETRA (LOPINAVIR AND RITONAVIR) TABLET, FILM COATED KALETRA (LOPINAVIR AND RITONAVIR) SOLUTION [ABBVIE INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8290add3-4449-4e58-6c97-8fe1eec972e3 | publisher = | date = | accessdate}}</ref> | ||
[[File:KALETRA Contraindications.jpg]] | [[File:KALETRA Contraindications.jpg|750px]] | ||
==References== | ==References== | ||
Latest revision as of 02:58, 10 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Contraindications
KALETRA is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir.
Co-administration of KALETRA is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions. Co-administration of KALETRA is contraindicated with potent CYP3A inducers where significantly reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and cross-resistance. These drugs are listed in Table 3.[1]
References
- ↑ "KALETRA (LOPINAVIR AND RITONAVIR) TABLET, FILM COATED KALETRA (LOPINAVIR AND RITONAVIR) SOLUTION [ABBVIE INC.]". Text " accessdate" ignored (help)
Adapted from the FDA Package Insert.